Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M163,615Revenue $M11,202Net Margin (%)45.5Z-Score9.4
Enterprise Value $M167,006EPS $1.8Operating Margin %58.6F-Score8
P/E(ttm))19.1Cash Flow Per Share $4.3Pre-tax Margin (%)56.7Higher ROA y-yY
Price/Book12.110-y EBITDA Growth Rate %0Quick Ratio1.8Cash flow > EarningsY
Price/Sales8.85-y EBITDA Growth Rate %8.2Current Ratio2.1Lower Leverage y-yN
Price/Cash Flow17.4y-y EBITDA Growth Rate %176ROA % (ttm)35.3Higher Current Ratio y-yY
Dividend Yield %0Insider Buy (3m)0ROE % (ttm)72.0Less Shares Outstanding y-yY
Payout Ratio %0Shares Outstanding M1,509ROI % (ttm)15.0Gross Margin Increase y-yY

Gurus Latest Trades with GILD

Number of guru portfolios checked: 84. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
GILDRonald Muhlenkamp 2014-09-30 Add1.19%$85.07 - $109.43
($97.98)
$ 108.4511%Add 42.59%206,350
GILDJoel Greenblatt 2014-09-30 Add0.21%$85.07 - $109.43
($97.98)
$ 108.4511%Add 42.28%664,223
GILDDavid Dreman 2014-09-30 Buy 0.02%$85.07 - $109.43
($97.98)
$ 108.4511%New holding, 2388 sh.2,388
GILDJohn Burbank 2014-09-30 Add0.01%$85.07 - $109.43
($97.98)
$ 108.4511%Add 219.9%12,073
GILDDodge & Cox 2014-09-30 Buy $85.07 - $109.43
($97.98)
$ 108.4511%New holding, 4800 sh.4,800
GILDKen Heebner 2014-09-30 Reduce-0.33%$85.07 - $109.43
($97.98)
$ 108.4511%Reduce -8.77%1,560,000
GILDVanguard Health Care Fund 2014-09-30 Reduce-0.28%$85.07 - $109.43
($97.98)
$ 108.4511%Reduce -76.79%379,200
GILDRay Dalio 2014-09-30 Reduce-0.07%$85.07 - $109.43
($97.98)
$ 108.4511%Reduce -30.96%241,521
GILDKen Fisher 2014-09-30 Reduce-0.04%$85.07 - $109.43
($97.98)
$ 108.4511%Reduce -21.74%763,423
GILDKen Heebner 2014-06-30 Buy 3.8%$65.48 - $83.02
($77.76)
$ 108.4540%New holding, 1710000 sh.1,710,000
GILDJulian Robertson 2014-06-30 Add2.98%$65.48 - $83.02
($77.76)
$ 108.4540%Add 28.55%443,911
GILDJoel Greenblatt 2014-06-30 Buy 0.48%$65.48 - $83.02
($77.76)
$ 108.4540%New holding, 466853 sh.466,853
GILDJohn Rogers 2014-06-30 Add0.25%$65.48 - $83.02
($77.76)
$ 108.4540%Add 60.78%638,734
GILDKen Fisher 2014-06-30 Add0.07%$65.48 - $83.02
($77.76)
$ 108.4540%Add 62.11%975,483
GILDRay Dalio 2014-06-30 Add0.06%$65.48 - $83.02
($77.76)
$ 108.4540%Add 41.22%349,821
GILDRonald Muhlenkamp 2014-06-30 Reduce-0.59%$65.48 - $83.02
($77.76)
$ 108.4540%Reduce -24.63%144,715
GILDVanguard Health Care Fund 2014-06-30 Reduce-0.21%$65.48 - $83.02
($77.76)
$ 108.4540%Reduce -39.79%1,633,700
GILDGeorge Soros 2014-06-30 Sold Out -0.04%$65.48 - $83.02
($77.76)
$ 108.4540%Sold Out0
GILDMariko Gordon 2014-06-30 Reduce-0.02%$65.48 - $83.02
($77.76)
$ 108.4540%Reduce -35.57%11,654
GILDJulian Robertson 2014-03-31 Add0.59%$68.55 - $83.95
($78.44)
$ 108.4538%Add 7.91%345,320
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

GILD is held by these Gurus:

Ticker Guru Name Portfolio Date* Current Shares % of Shares Outstanding % of Total Assets Managed Change from Last Holdings Holding History
GILD David Dreman 2014-09-302,38800.02New Buy
GILD Dodge & Cox 2014-09-304,80000New Buy
GILD John Burbank 2014-09-3012,07300.02+219.9%
GILD Ronald Muhlenkamp 2014-09-30206,3500.014+42.59%
GILD Joel Greenblatt 2014-09-30664,2230.040.7+42.28%
GILD John Rogers 2014-09-30643,8960.040.88+0.81%
GILD Julian Robertson 2014-09-30443,9110.0312.5
GILD Jean-Marie Eveillard 2014-09-3040000
GILD Ken Heebner 2014-09-301,560,0000.14.7-8.77%
GILD Mariko Gordon 2014-09-3010,36600.05-11.05%
GILD Mario Gabelli 2014-09-3042,60000.02-13.36%
GILD Ken Fisher 2014-09-30763,4230.050.17-21.74%
GILD Ray Dalio 2014-09-30241,5210.020.2-30.96%
GILD Vanguard Health Care Fund 2014-09-30379,2000.030.1-76.79%
Premium Most recent portfolio changes are included for Premium Members only!


GILD: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
MILLIGAN JOHN FPresident and COO 2014-12-08Sell146,823$106.262.06view
MARTIN JOHN CChairman and CEO 2014-12-01Sell140,633$100.727.67view
Alton Gregg HEVP, Corp & Med Affairs 2014-12-01Sell33,000$100.797.6view
Carter Paul RutherfordEVP Commercial Ops 2014-12-01Sell2,000$100.028.43view
Whitley Richard JamesDirector 2014-12-01Sell5,000$100.198.24view
Cogan John FrancisDirector 2014-11-21Sell25,000$101.237.13view
MILLIGAN JOHN FPresident and COO 2014-11-07Sell146,895$107.371.01view
Alton Gregg HEVP, Corp & Med Affairs 2014-11-03Sell33,000$110.5-1.86view
Whitley Richard JamesDirector 2014-11-03Sell5,000$112.02-3.19view
MARTIN JOHN CChairman and CEO 2014-11-03Sell140,625$110.4-1.77view

Press Releases about GILD :

Quarterly/Annual Reports about GILD:

News about GILD:

Articles On GuruFocus.com
Is it Time to Sell Gilead Sciences? Dec 18 2014 
Druckenmiller Adds Healthcare Stocks to Portfolio Dec 15 2014 
Weekly CFO Sells Highlight: Coco-Cola Co, Gilead Sciences Inc, AutoZone Inc. Dec 14 2014 
Weekly Insider Sells Highlight: WAT, KO, GILD, AZO, MAS Dec 14 2014 
T Rowe Price's Top Stakes for the Third Quarter Dec 09 2014 
3 Strong Buys and Sells Dec 08 2014 
Gilead Sciences' Recent Plunge Makes It One of The Hot Stocks To Buy Dec 01 2014 
now Nov 29 2014 
Weekly CFO Sells Highlight: Tableau Software Inc, Gilead Sciences Inc, Facebook Inc. Nov 16 2014 
Gilead Sciences Releases Impressive Results for Hepatitis C Drug Nov 12 2014 


More From Other Websites
U.S. FDA approves AbbVie hepatitis C drug, costs $83,319 for 12 weeks Dec 19 2014
AbbVie's Hepatitis-C Treatment Approved, Bad news for Gilead? Dec 19 2014
United Therapeutics Lung Drug Keeps Going And Going Dec 19 2014
Abbvie's Hep C Regimen Approved, Marketing Battle With Gilead Up Next Dec 19 2014
Stocks Press Higher; Biotechs Gilead, Biogen Rise Dec 19 2014
U.S. FDA approves AbbVie all-oral hepatitis C treatment Dec 19 2014
Stocks Off Highs But Stay Positive; Nike Drags Dow Dec 19 2014
Gilead Sciences: Why Cancer Drug Licensing is a Good Start Dec 19 2014
Cramer's Mad Dash: Tale of two biotechs Dec 19 2014
The best CEOs of 2014 Dec 19 2014
Gilead is Accused of Price Gouging, but is There Really a Legal Argument? Dec 19 2014
6:02 am Gilead Sciences and Ono Pharma (OPHLY) announced that... Dec 19 2014
ONO and Gilead Announce Exclusive License Agreement to Develop BTK Inhibitor, ONO-4059, for the... Dec 19 2014
ONO AND GILEAD ANNOUNCE EXCLUSIVE LICENSE AGREEMENT TO DEVELOP BTK INHIBITOR, ONO-4059, FOR THE... Dec 19 2014
ONO and Gilead Announce Exclusive License Agreement to Develop BTK Inhibitor, ONO-4059, for the... Dec 19 2014
ONO and Gilead Announce Exclusive License Agreement to Develop BTK Inhibitor, ONO-4059, for the... Dec 19 2014
Lawsuit Alleges Price Gouging by Maker of Hepatitis Drug Dec 19 2014
Drug’s Price Sparks Lawsuit Dec 18 2014
CVS' Plan to Foment a Hep C Pricing War Between Gilead, Abbvie Dec 18 2014
Biotech: More Upside in 2015? Dec 18 2014

Add Notes, Comments

If you want to ask a question, or report a bug, please create a support ticket.

User Comments

No comment yet
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK